Recent Advances in the Synthesis of High Boron-Loaded Nucleic Acids for BNCT

Boron clusters attract considerable attention as promising therapeutic tools for boron neutron capture therapy (BNCT). They combine high boron content with high chemical and biological stability, biorthogonality, and low toxicity. The development of oligonucleotide-based constructs and nucleic acid-like molecules, such as oligomeric phosphate diesters, bearing one or multiple boron clusters permits to create potential high boron-loaded agents for BNCT with good bioavailability, specifically interacting with nucleic acids inside the cell. Here, we shortly review the strategies and solutions in the design of oligonucleotide conjugates with boron clusters in light of the requirements for effective BNCT and future prospects of their practical use.

Automated summary

Boron clusters show promise as therapeutic tools for BNCT due to their high boron content, stability, and low toxicity. By developing oligonucleotide constructs with boron clusters, high boron-loaded agents can be created that interact specifically with nucleic acids in cells, offering new possibilities for BNCT treatments.